【摘要】 目的:探讨初治卵巢癌组织多药耐药基因（MDR₁）表达水平及其对相关药物抗肿瘤作用的影响.方法:用逆转录酶链聚合反应（RT—PCR）法对37例初治卵巢癌组织MDR₁表达水平进行了定量测定.结果:37例卵巢癌组织均有MDR₁表达,其中浆液性癌的表达水平为0.75±0.22,粘液性癌为1.03±0.28,内膜样癌为0.57±0.11,3种病理类型之间MDR₁的表达水平有显著性差异（P<0.05）;34例卵巢癌的小鼠肾包膜下移植肿瘤药敏测定（SRCA）肿瘤药敏试验成功,此34例的MDR₁表达水平与ADM及VCR在SRCA中的抗肿瘤作用呈负相关,与VP16的抗肿瘤作用无相关关系.结论:初治卵巢癌存在固有的MDR₁表达,MDR₁的表达降低相关药物的抗肿瘤作用.更多还原

【Abstract】 Objective:To investigate the expresson level of MDR₁ in Ovarian Carcinoma and its effection on the antitumor ac-tivity of MDR₁ reltated drugs. Methods: The MDR₁ gene expression in fresh ovarian carcinom spemens from 37 patients were analyzed by reverse transcription polymerase chain reaction, and the antitumor activity of three MDR₁ related drug （ADM. VCR. VP16） was mesaurde by subrenal capsule assay. Results; The MDR₁ expression was demonstrated in all 37 case of ovarian carcinomas; The MDR₁ /? actin in serious Carcimoma was 0.75 ?0.22, in mucious carcinoma 1.03 ?0.28, in endometrioid carcinoma 0.57 ?0.11, there were significant differences among the three histological subtypes（P<0.05）; Negative correlations were found between the MDR₁ expression level （specially in high） and the antitumor activity of ADM and VCR in subrenal capsule assay. Conclusion:There are intrinsic MDR₁ expression in all untreated ovarian carcinomas, and the MDR₁ expression may lead the chemoresistance of MDR₁ related drug. Therefore, MDR₁ related drugs should combined with MDR₁ reverse agents and MDR₁ unrelated drugs in the overian carcinoma treatment at the very begining.更多还原